The Latest Breaking News from Alzheimer Disease

Although age is by far the greatest risk factor for dementia, obesity and type 2 diabetes are also major risk factors

Over 55 million people worldwide have dementia. This mind-robbing condition has a huge impact on society and the economy, so scientists are working hard to find ways to treat or prevent it. One of the avenues being explored is the new weight-loss jab, Wegovy.

Donanemab was shown in a late-stage trial to slow cognitive decline more than a third

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

New drug donanemab appears to slow decline associated with Alzheimer’s

Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.

"This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline," Eli Lilly said.